Epoch Biodesign Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 56

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $12M

  • Investors
  • 30

Epoch Biodesign General Information

Description

Operator of industrial biotechnology services intended to address the environmental and economic challenges posed by plastic waste. The company designs and develops enzymes by combining biology, artificial intelligence, and engineering capable of breaking down plastics into reusable chemicals, enabling industries to reduce plastic waste and enhance sustainability.

Contact Information

Formerly Known As
Mellizyme Biotechnology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 10 Finsbury Square
  • London EC2 1AJ
  • England, United Kingdom
+44 020
Primary Industry
Environmental Services (B2B)
Corporate Office
  • 10 Finsbury Square
  • London EC2 1AJ
  • England, United Kingdom
+44 020

Epoch Biodesign Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Epoch Biodesign Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Later Stage VC 25-Mar-2026 $12M Completed Generating Revenue
14. Accelerator/Incubator 01-Mar-2026 Completed Generating Revenue
13. Later Stage VC (Series A1) 06-Mar-2025 Completed Generating Revenue
12. Grant 05-Mar-2025 Completed Generating Revenue
11. Later Stage VC (Series A2) 16-Dec-2024 Completed Generating Revenue
10. Accelerator/Incubator 20-Mar-2024 Completed Generating Revenue
9. Seed Round 14-Dec-2021 Completed Generating Revenue
8. Grant 01-Mar-2021 Completed Startup
7. Seed Round 30-Jan-2021 $3.67M $3.99M Completed Startup
6. Seed Round 19-Jan-2021 $321K Completed Startup
To view Epoch Biodesign’s complete valuation and funding history, request access »

Epoch Biodesign Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1
Series A2
Seed Preferred
Seed Ordinary
Ordinary 30,000 $0.000126 $6.29 $6.29 1x $6.29 1.1%
Ordinary 363,221 $0.000126 $8.8 $8.8 1x $8.8 13.37%
To view Epoch Biodesign’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Epoch Biodesign Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of industrial biotechnology services intended to address the environmental and economic challenges posed by pla
Environmental Services (B2B)
London, United Kingdom
56 As of 2026

Berkeley, CA
 

Chaponost, France
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Epoch Biodesign Competitors (2)

One of Epoch Biodesign’s 2 competitors is Shiru, a Venture Capital-Backed company based in Berkeley, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Shiru Venture Capital-Backed Berkeley, CA
SYMATESE Formerly PE-Backed Chaponost, France
You’re viewing 2 of 2 competitors. Get the full list »

Epoch Biodesign Patents

Epoch Biodesign Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202505703-D0 Recycling processes Pending 16-Apr-2025
GB-202418775-D0 Processes and enzymes for use therein Pending 19-Dec-2024
WO-2026132812-A1 Processes and enzymes for use therein Pending 19-Dec-2024
GB-202402694-D0 Recycling processes Inactive 26-Feb-2024
GB-202314258-D0 Recycling methods and products Inactive 18-Sep-2023
To view Epoch Biodesign’s complete patent history, request access »

Epoch Biodesign Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Epoch Biodesign Investors (30)

Investor Name Investor Type Holding Investor Since Participating Rounds
Leitmotif Venture Capital Minority
Lululemon Studio Corporation Minority
Tech Nation Group Accelerator/Incubator
Extantia Capital Impact Investing Minority
Kibo Invest Family Office Minority
You’re viewing 5 of 30 investors. Get the full list »

Epoch Biodesign Acquisitions (1)

Epoch Biodesign’s most recent deal was a Merger/Acquisition with Domo Polymer Solution Spain for . The deal was made on 11-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Domo Polymer Solution Spain 11-Jun-2026 Merger/Acquisition Industrial Chemicals
To view Epoch Biodesign’s complete acquisitions history, request access »

Epoch Biodesign FAQs

  • When was Epoch Biodesign founded?

    Epoch Biodesign was founded in 2019.

  • Where is Epoch Biodesign headquartered?

    Epoch Biodesign is headquartered in London, United Kingdom.

  • What is the size of Epoch Biodesign?

    Epoch Biodesign has 56 total employees.

  • What industry is Epoch Biodesign in?

    Epoch Biodesign’s primary industry is Environmental Services (B2B).

  • Is Epoch Biodesign a private or public company?

    Epoch Biodesign is a Private company.

  • What is Epoch Biodesign’s current revenue?

    The current revenue for Epoch Biodesign is .

  • How much funding has Epoch Biodesign raised over time?

    Epoch Biodesign has raised $64.1M.

  • Who are Epoch Biodesign’s investors?

    Leitmotif, Lululemon Studio, Tech Nation Group, Extantia Capital, and Kibo Invest are 5 of 30 investors who have invested in Epoch Biodesign.

  • Who are Epoch Biodesign’s competitors?

    Shiru and SYMATESE are competitors of Epoch Biodesign.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process